CYTOKINETICS INC
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
CYTK$56.18+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data) (Unaudited)
| Three Months Ended | ||
|---|---|---|
| March 31, 2024 | March 31, 2023 | |
| Revenues: | ||
| Research and development revenues | $835 | $2,113 |
| Milestone revenues | — | 2,500 |
| Total revenues | 835 | 4,613 |
| Operating expenses: | ||
| Research and development | 81,570 | 79,421 |
| General and administrative | 45,500 | 49,665 |
| Total operating expenses | 127,070 | 129,086 |
| Operating loss | (126,235) | (124,473) |
| Interest expense | (7,103) | (6,961) |
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | (10,218) | (6,280) |
| Interest and other income, net | 7,913 | 6,425 |
| Net loss | $(135,643) | $(131,289) |
| Net loss per share — basic and diluted | $(1.33) | $(1.38) |
| Weighted-average number of shares used in computing net loss per share — basic and diluted | 101,924 | 95,164 |
| Other comprehensive (loss) gain: | ||
| Unrealized (loss)/gain on available-for-sale securities, net | (556) | 1,945 |
| Foreign currency translation adjustments | 27 | — |
| Comprehensive loss | $(136,172) | $(129,344) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.